item management s discussion and analysis of financial condition and results of operations overview since commencing operations in  the company has been engaged principally in the research and development of its product candidates as well as seeking various regulatory clearances and patent protection 
the company has had no revenues from product sales and has incurred losses since inception through december  aggregating approximately million 
the company has received revenues in connection with various licensing and collaboration agreements 
in august  the company entered into a strategic alliance with mallinckrodt pursuant to which it received million in up front license fees 
the agreement provided for an additional million milestone payment which was received in july in march  the company entered into a strategic alliance with daiichi 
under this agreement  the company received million in license fees and million from the sale of shares of the company s preferred stock  and was entitled to receive up to million in future payments based upon the company s achievement of certain product development milestones 
the company received  of such milestone payments in july the company expects continued operating losses for the next several years as it incurs expenses to support research  development and efforts to obtain regulatory approvals 
the company s initial product candidate  ms  is currently the company s only product candidate undergoing human clinical trials 
the company filed an ind application for ms in july the company initiated a phase i clinical trial in and a phase i dose escalation study in both of which have been completed 
the company started a phase ii trial for peripheral vascular disease indications in june and has since commenced feasibility clinical trials for both cardiac and breast cancer indications 
in  the company changed its fiscal year end from march to december the company anticipates fluctuation in its quarterly results of operations due to several factors  including the timing of fees and milestone payments received from strategic partners  the formation of new strategic alliances by the company  the timing of expenditures in connection with research and development activities  the timing of product introductions and associated launch  marketing and sales activities  and the timing and extent of product acceptance for different indications and geographical areas of the world 
results of operations comparison of year ended december  and year ended december  revenues revenues for the annual period included milestone payments of million received from mallinckrodt inc and  received from daiichi radioisotope laboratories  ltd 
pursuant to collaboration agreements covering the company s lead product  ms revenues for the year ended december  consisted principally of a million license fee received from mallinckrodt and a million licensee fee from daiichi  each related to the formation of the collaboration agreements covering ms annual revenues also include million and million of ms development contract revenue earned from strategic partners in and  respectively 
research and development expenses research and development expenses for the year ended december  were million as compared to million for the increase resulted principally from additional costs for personnel and resources to support research in the area of thrombus imaging and the development of core technology 
higher costs associated with advancing ms through clinical trials also contributed to higher research and development expenses in general and administrative expenses general and administrative expenses for the year ended december  were million as compared to million for higher expenses in were largely the result of the costs associated with the formation of two major strategic collaborations 
in addition  general and administrative expenses included a  non recurring expense related to the restructuring of a licensing arrangement under a liver agent development program that was terminated in partially offsetting these items were higher expenses in for ongoing patent protection activities  and the additional costs of becoming and operating as a publicly held company 
interest income and expense interest income for the year ended december  was million as compared to  for the million increase was primarily due to higher average levels of invested cash during interest expense for the year ended december  was  as compared to  in the period included interest on borrowings under promissory notes and bridge loans which were outstanding during the first five months of comparison of year ended december  and nine months ended december  revenues 
revenues for the year ended december  were million as compared to  for the nine month fiscal period ended december  revenues for the year ended december  included million in license fees and approximately million of development contract revenue from mallinckrodt 
revenues during also included million in license fees net of foreign withholding tax received from daiichi for the rights to commercialize ms in japan 
revenues for the nine month period ended december  consisted entirely of payments received from a pharmaceutical company as consideration for an option for certain rights to the company s future contrast agents in japan 
the option expired and the rights to the agent were subsequently licensed to a third party 
research and development expenses 
research and development expenses for the year ended december  were million  as compared to million for the nine month period ended december  this increase was due primarily to increased ms development costs associated with the commencement of phase i clinical trials in september general and administrative expenses 
general and administrative expenses for the year ended december  were million as compared to million for the nine month period ended december  the million increase was largely due to increased personnel costs associated with recruitment and compensation of additional senior management and increased expenses for strategic consulting and business development activities 
significant secondary causes of the increase include higher patent costs as well as increased agency fees and legal expenses associated principally with the formation of collaborative agreements 
in addition  general and administrative expenses for included  of nonrecurring expense incurred in connection with the restructuring of a liver agent development program which was terminated by the company in interest income and expense 
interest income for the year ended december  was  as compared to  for the nine month period ended december  this increase was due to higher average cash available for investment during interest expense for the year ended december  was  as compared to  for the nine month period ended december  this increase was due to higher borrowings during under promissory notes and bridge loans 
liquidity and capital resources the company financed its operations from inception through december  primarily with million in net proceeds from the company s initial public offering completed in february  million from a follow on public offering of common stock in november  million from private sales of equity securities  million received from third parties in connection with collaboration and license arrangements  million of equipment lease financing and million in interest income 
from inception through december   the company has incurred million of costs attributable to operating activities  including million related to the research and development of technology and new product candidates  including ms the company s principal source of liquidity consists of cash  cash equivalents and marketable securities which totaled million at december   as compared to million at december  the company is eligible to receive additional payments of million from daiichi upon the attainment of certain future ms development milestones 
daiichi is responsible for funding development of ms in japan 
under the company s agreement with mallinckrodt  mallinckrodt and the company will generally share equally in future development costs of ms up to a specified maximum amount 
during the year ended december   the company used approximately million of cash for operating activities  exclusive of license fee revenues 
the company expects that its cash needs for operations will increase significantly in future periods due to planned clinical trials and other expenses associated with the development of ms and new research and development programs 
the company estimates that existing cash  cash equivalents and marketable securities  will be sufficient to fund its operations through the second quarter of the company believes that it will need to raise additional funds for research  development and other expenses  through equity or debt financings  strategic alliances or otherwise  prior to commercialization of any of its product candidates 
there can be no assurance that additional financing will be available on terms acceptable to the company  or at all 
the company s future liquidity and capital requirements will depend on numerous factors  including the following the progress and scope of clinical trials  the timing and costs of filing future regulatory submissions  the timing and costs required to receive both united states and foreign governmental approvals  the cost of filing  prosecuting  defending and enforcing patent claims and other intellectual property rights  the extent to which the company s products gain market acceptance  the timing and costs of product introductions  the extent of the company s ongoing research and development programs  the costs of training physicians to become proficient with the use of the company s products  and  if necessary  once regulatory approvals are received  the costs of developing marketing and distribution capabilities 
because of anticipated spending to support development of ms and new research programs  the company does not expect positive cash flow from operating activities for any future quarterly or annual period prior to commercialization of ms the company anticipates continued investments in fixed assets  including equipment and facilities expansion to support new and continuing research and development programs 
in july  the company reached an agreement which will enable it to lease its current principal scientific facilities through december  the company has a short term lease for a nearby office space which expires in october but is renewable under certain conditions for an additional month period 
the company has reported only tax losses to date and therefore has not paid significant federal or state income taxes since inception 
at december   the company had loss carryforwards of approximately million available to offset future taxable income 
these amounts expire at various times through as a result of ownership changes resulting from sales of equity securities  the company s ability to use the loss carryforwards is subject to limitations as defined in sections and of the internal revenue code of  as amended the code 
the company currently estimates that the annual limitation on its use of net operating losses through may  will be approximately  pursuant to sections and of the code  the change in ownership resulting from public equity offerings in and any other future ownership changes may further limit utilization of losses and credits in any one year 
the company is also eligible for research and development tax credits which can be carried forward to offset federal taxable income 
the annual limitation and the timing of attaining profitability may result in the expiration of net operating loss and tax credit carryforwards before utilization 
the company does not believe that inflation has had a material impact on its operations 
the company has performed a preliminary internal review of its computer systems for the potential consequences associated with year issues 
based on this review  the company does not believe that the year will have a material impact on its operations 
the company is currently conducting a more in depth study to confirm this preliminary finding 
the discussion included in this section as well as elsewhere in the annual report on form k may contain forward looking statements based on current expectations of the company s management 
such statements are subject to risks and uncertainties which could cause actual results to differ from those projected 
see factors regarding forward looking statements attached hereto as exhibit and incorporated by reference into this form k 
readers are cautioned not to place undue reliance on the forward looking statements which speak only as the date hereof 
the company undertakes no obligation to publicly release the result of any revisions to these forward looking statements which may be made to reflect events or circumstances occurring after the date hereof or to reflect the occurrence of unanticipated events 
item a 
quantitative and qualitative disclosures about market risk not applicable 

